Apuli Maricel 4

What Happened
Apuli Maricel, Chief Accounting Officer of BridgeBio Pharma, was granted 14,170 restricted stock units (RSUs) on 2026-03-18. The RSUs were granted at $0.00 (no cash paid); each RSU is a contingent right to one share of common stock, so the grant corresponds to 14,170 potential shares. This is an equity award (compensation), not an open-market purchase or sale.

Key Details

• Transaction date: 2026-03-18; Filing date: 2026-03-20 (appears timely—filed within two business days).
• Grant size: 14,170 RSUs; grant price reported as $0.00; immediate cash value at grant: $0.
• Vesting: RSUs vest 1/16th of the underlying shares on May 16, 2026, then 1/16th each quarter thereafter until fully vested, subject to continued service. RSUs have no expiration date. (Footnotes: F1, F2)
• Each RSU equals one share upon settlement.
• Shares owned after the transaction: not disclosed in the provided filing.
• No tax withholding, 10b5-1 plan, or sale reported in this filing.

Context
RSU grants are routine executive compensation and do not by themselves signal a buy or sell preference by the insider. The award vests over time contingent on continued service; once vested and settled, those RSUs convert to common shares. Retail investors typically view grants as part of pay/retention programs rather than immediate insider market activity.